Hydroxychloroquine and COVID-19 - A narrative review

Area of Science:

• Infectious Diseases
• Pharmacology
• Cardiology

Background:

• COVID-19 remains a significant global health crisis with limited therapeutic options.
• Early use of hydroxychloroquine (HCQ) for COVID-19 was based on preliminary data, lacking robust clinical evidence.
• The need for effective treatments necessitates rigorous evaluation of existing and novel drug candidates.

Purpose of the Study:

• To review the mechanism of action of hydroxychloroquine in the context of COVID-19.
• To critically analyze existing clinical studies on hydroxychloroquine for COVID-19 treatment.
• To discuss cardiac toxicity, guidelines, and future research directions for HCQ in COVID-19 management.

Main Methods:

• Literature review of pharmacological mechanisms.
• Analysis of observational and randomized controlled trials.
• Examination of reported adverse events and clinical guidelines.

Main Results:

• Limited clinical evidence supports the unequivocal benefit of hydroxychloroquine for COVID-19.
• Concerns regarding cardiac toxicity necessitate careful patient selection and monitoring.
• Paucity of data highlights the need for large-scale clinical trials.

Conclusions:

• Hydroxychloroquine's role in COVID-19 treatment remains uncertain due to insufficient evidence of efficacy.
• Further large-scale clinical trials are essential to ascertain the benefits and risks of hydroxychloroquine.
• Understanding HCQ's cardiac effects is crucial for safe clinical application in viral infections.